Opinion
Video
Abiraterone Acetate Versions for Treatment of mCRPC
Author(s):
This video segment explores how to choose between the original brand, generic, and micronized versions of abiraterone, considering factors like efficacy, cost, patient preference, and clinical context.
Video Player is loading.
Video content above is prompted by the following:
- Abiraterone is now available as the original brand, generic and micronized versions. How do you choose between these different options of abiraterone?
Related Videos
Case 1: A 79-Year-Old Man With Non–Muscle-Invasive Bladder Cancer
An Overview Of Pembrolizumab for High-Risk BCG Unresponsive NMIBC
Case 2: A 63-Year-Old Man With Recurrent HSPC
Comorbidities and Adherence: Tailoring mHSPC Treatment
FDA-Approved Options for High-Risk BCG-Unresponsive NMIBC
Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
Treatment or Lack of Treatment of Small Renal Masses
The current treatment landscape of mHSPC
Strengths and Weaknesses of Imaging Modalities in ccRCC
BPH: Strategies for Guiding Patients From Medication to Intervention
Related Content
